Esperion Therapeutics (ESPR) Other Non-Current Assets (2019 - 2022)

Esperion Therapeutics' Other Non-Current Assets history runs 4 years deep, the most recent figure standing at $50.0 million for Q3 2022.

• Quarterly Other Non-Current Assets changed 0.0% year-over-year to $50.0 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $50.0 million (changed 0.0% YoY) and the FY2021 annual result came in at $50.0 million, changed N/A from the prior year.
• Other Non-Current Assets was $50.0 million for Q3 2022 at Esperion Therapeutics, roughly flat from $50.0 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $50.0 million in Q3 2021 and bottomed at $928000.0 in Q2 2019.
• A 4-year average of $23.3 million and a median of $1.3 million in 2020 frame the typical range for Other Non-Current Assets.
• Peak annual rise in Other Non-Current Assets reached 39.44% in 2020, while the deepest fall reached 22.21% in 2020.
• Esperion Therapeutics' Other Non-Current Assets stood at $928000.0 in 2019, then soared by 39.44% to $1.3 million in 2020, then surged by 3763.99% to $50.0 million in 2021, then changed by 0.0% to $50.0 million in 2022.
• Business Quant data shows ESPR's Other Non-Current Assets at $50.0 million in Q3 2022, $50.0 million in Q2 2022, and $50.0 million in Q1 2022.